These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3724664)

  • 21. [Dynamics of antigen and antibody accumulation in adult mice, infected with Lassa virus].
    Vladyko AS; Surikova LE; Kramarenko LP; Bystrova SI; Torop AV
    Vopr Virusol; 1989; 34(1):100-3. PubMed ID: 2658319
    [No Abstract]   [Full Text] [Related]  

  • 22. Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin.
    Jahrling PB
    J Med Virol; 1983; 12(2):93-102. PubMed ID: 6619814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of Lassa fever vaccine candidates.
    Salami K; Gouglas D; Schmaljohn C; Saville M; Tornieporth N
    Curr Opin Virol; 2019 Aug; 37():105-111. PubMed ID: 31472333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies.
    Ruo SL; Mitchell SW; Kiley MP; Roumillat LF; Fisher-Hoch SP; McCormick JB
    J Gen Virol; 1991 Mar; 72 ( Pt 3)():549-55. PubMed ID: 1706408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Scholte FEM; Goldsmith CS; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2019 Sep; 220(8):1281-1289. PubMed ID: 31152662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine platforms to control Lassa fever.
    Lukashevich IS; Pushko P
    Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
    Pushko P; Geisbert J; Parker M; Jahrling P; Smith J
    J Virol; 2001 Dec; 75(23):11677-85. PubMed ID: 11689649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The indirect hemagglutination reaction for the detection of the Lassa virus].
    Vladyko AS; Kramarenko LP; Cherednichenko IA; Surikova LE
    Vopr Virusol; 1988; 33(4):498-502. PubMed ID: 3195147
    [No Abstract]   [Full Text] [Related]  

  • 29. Lassa fever virus: properties and characteristics.
    Tomori O; Fabiyi A
    Niger Med J; 1979 Jan; 9(1):17-9. PubMed ID: 111436
    [No Abstract]   [Full Text] [Related]  

  • 30. [The dynamics of the formation of IgG subclasses in Balb/c and CBA mice infected with the LCM, Lassa and Mopeia viruses and their role in diagnosis].
    Zaĭtseva VN; Bystrova SI; Shkolina TV; Vladyko AS
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (1):47-51. PubMed ID: 9221657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Ippy as a Lassa-fever-related virus.
    Swanepoel R; Leman PA; Shepherd AJ; Shepherd SP; Kiley MP; McCormick JB
    Lancet; 1985 Mar; 1(8429):639. PubMed ID: 2857974
    [No Abstract]   [Full Text] [Related]  

  • 32. Serological survey for the detection of antibodies to lassa virus in India.
    Rodrigues FM; Gupta NP; Pinto BD
    J Indian Med Assoc; 1978 Jan; 70(2):25-8. PubMed ID: 659905
    [No Abstract]   [Full Text] [Related]  

  • 33. Protection of guinea pigs inoculated with Tacaribe virus against lethal doses of Junin virus.
    Coto CE; Damonte EB; Catello MA; Weissenbacher MC
    J Infect Dis; 1980 Mar; 141(3):389-93. PubMed ID: 6245155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation and use of erythrocyte-globulin conjugates to Lassa virus in reversed passive hemagglutination and inhibition.
    Goldwasser RA; Elliott LH; Johnson KM
    J Clin Microbiol; 1980 Jun; 11(6):593-9. PubMed ID: 7000810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential Immune Responses to New World and Old World Mammalian Arenaviruses.
    Ly H
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28498311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
    Wang M; Jokinen J; Tretyakova I; Pushko P; Lukashevich IS
    Vaccine; 2018 Jan; 36(5):683-690. PubMed ID: 29287681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiation between two African arenaviruses (Lassa and Mozambique) by plaque assay.
    Tomori O; Johnson K
    Acta Virol; 1987 Mar; 31(2):146-51. PubMed ID: 2886023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective vaccine for lassa fever.
    Fisher-Hoch SP; Hutwagner L; Brown B; McCormick JB
    J Virol; 2000 Aug; 74(15):6777-83. PubMed ID: 10888616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
    Bredenbeek PJ; Molenkamp R; Spaan WJ; Deubel V; Marianneau P; Salvato MS; Moshkoff D; Zapata J; Tikhonov I; Patterson J; Carrion R; Ticer A; Brasky K; Lukashevich IS
    Virology; 2006 Feb; 345(2):299-304. PubMed ID: 16412488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lassa virus antibodies in hospital personnel in western Liberia.
    Frame JD; Casals J; Dennis EA
    Trans R Soc Trop Med Hyg; 1979; 73(2):219-24. PubMed ID: 382467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.